Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, cytarabine, imatinib mesylate
Biological · Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Myelogenous Leukemia
Interventions
Imatinib, Nilotinib (AMN107)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Tucson, Arizona • Anaheim, California • Baldwin Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Interventions
Asciminib, Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
9
States / cities
Denver, Colorado • Peoria, Illinois • Saint Paul, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
dasatinib, diagnostic laboratory biomarker analysis, pharmacological study, cyclosporine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Polycythemia Vera, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic
Interventions
nilotinib, imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Vallejo, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib followed by treatment-free
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Myeloid Leukemia, Philadelphia Positive
Interventions
Asciminib Pediatric formulation group, Asciminib Adult formulation group
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Juvenile Myelomonocytic Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Disease
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
nilotinib, cytogenetic analysis, mutation analysis, polymerase chain reaction, pharmacological study
Drug · Genetic · Other
Lead sponsor
Cancer Trials Ireland
Network
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
Asciminib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22)
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Methotrexate, Prednisone, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Belinostat, Azacitidine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced May 22, 2026, 1:08 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced May 22, 2026, 1:08 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Myeloid Sarcoma, Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
Interventions
Cladribine, Cytarabine, Dexrazoxane Hydrochloride, Gemtuzumab Ozogamicin, Idarubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 22, 2026, 1:08 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Amarillo, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
62
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced May 22, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Anaheim, California • Loma Linda, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced May 22, 2026, 1:08 AM EDT